Sun Pharma presents LEQSELVI data and Geojit targets Sun Pharma stock at INR 2,070

Published on 10/05/2026 at 18:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 fiscal 2027 revenue rose 10.50 percent to INR 15.30 billion. Sun Pharma stock had an INR 4.3 trillion market value on October 5, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma presented two-year LEQSELVI data on October 5, 2026, while Geojit set an INR 2,070 target for Sun Pharma stock in a report dated September 21, 2026. The data showed that 93.90 percent of baseline responders who maintained their response at Week 52 also maintained it at Week 108.

LEQSELVI shows durable response

According to PharmaTutor on October 5, 2026, Sun Pharma featured LEQSELVI in seven presentations at the European Academy of Dermatology and Venereology Congress. The oral treatment is being studied in adults with severe alopecia areata, and the company reported that its safety profile through two years remained consistent with earlier clinical experience.

The same report said 76.60 percent of patients who did not respond at baseline achieved a response by Week 52. Among those patients who continued after responding, 96.80 percent maintained the response through Week 108, giving the new data a clear durability angle.

Quarterly growth supports target

Sun Pharma reported consolidated revenue from operations of INR 15.30 billion in the first quarter of fiscal 2027, up 10.50 percent from INR 13.85 billion in the first quarter of fiscal 2026. Net profit reached INR 2.89 billion, up 27.00 percent from INR 2.28 billion, according to Cruxal in its results report dated September 22, 2026.

Moneycontrol reported on September 21, 2026, that Geojit retained a buy rating and revised its target to INR 2,070. The broker cited 10.50 percent first-quarter revenue growth, 22.00 percent sales from Global Specialty and a 28.10 percent EBITDA margin, while noting that the margin was affected by the absence of a prior-year lenalidomide benefit.

Market value reaches INR 4.3 trillion

Sun Pharma had a market capitalization of INR 4.3 trillion as of October 5, 2026. The latest structured quote showed INR 1,779.70 on the NSE, down INR 21.30, or 1.18 percent, from the prior close of INR 1,801.00, with a 52-week range of INR 1,583.70 to INR 2,046.90.